20 April 2016 - The EMA has published information on applications for centralised marketing authorisation for human medicines that the agency has received for evaluation.

It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the CHMP. For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area. This list only includes information for medicines whose applications have been validated at the time the report was compiled.

The information in the updated report was compiled on 13 April 2016.

For more details, go to: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/04/WC500205031.pdf